Innoviva, Inc. · NASDAQ:INVA
Innoviva — Investor Presentation (August 2026)
30 slides from Innoviva's investor presentation, August 2026
Slide 1: Corporate Presentation
Corporate Presentation August 2026
Slide 2: Forward-looking statements
Forward-looking statements The information in this presentation contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securities Act”). Such forward looking statements
Slide 3: Innoviva at a glance
Innoviva at a glance 1. Strongly cash-flow-positive, durable core royalty business stemming from widely used respiratory products 2. Commercial-stage, fast-growth critical care and infectious disease platform 3. High-potential, valuable portfolio of healthcare assets 4. Thoughtful, robust approach t
Slide 4: Innoviva is a diversified biopharmaceutical company with valuable synergistic businesses
Innoviva is a diversified biopharmaceutical company with valuable synergistic businesses Innoviva Specialty Strategic healthcare Royalty assets Therapeutics (IST) assets Durable royalty stream from two widely Robust, growing therapeutics platform Diversified portfolio of promising healthcare used, d
Slide 5: Three unique business divisions provide high growth potential with robust downside protection
Three unique business divisions provide high growth potential with robust downside protection High growth assets with Biopharma exposure without the Proven operational and investment significant upside binary risk track record • Specialty therapeutics business • Profitable and well-capitalized • Dem
Slide 6: Our core businesses have demonstrated strong top line growth and resilience
Our core businesses have demonstrated strong top line growth and resilience Annual revenue, $M Commentary • Strong organic growth Giapreza Xerava Xacduro Zevtera Ex-US sales and license revenue driven by re-energized commercial efforts for 175 Giapreza and successful Xacduro launch 117 IST 50% • Add
Slide 7: Our royalty assets have produced durable, resilient revenues
Royalty Assets Our royalty assets, composed of widely used respiratory therapies commercialized by GSK, have produced durable, resilient revenues that are de-risked via geographic and drug class diversification 5-year consensus 5-year projected Product LTM1 global net sales Royalty rate projected sa
Slide 8: Relvar/Breo and Anoro are protected by an IP estate with meaningful remaining exclusivity
Royalty Assets Relvar/Breo and Anoro are protected by an IP estate with meaningful remaining exclusivity Primary US Key secondary Potential The terms of the Expiration collaboration agreement with patent US patent expiration GSK indicate that royalties will be paid until the later of: RELVAR®/ Vilan
Slide 9: IST is a robust, rapidly growing critical care and infectious disease business
Innoviva Specialty Therapeutics Assets IST is a robust, rapidly growing critical care and infectious disease business Differentiated, complementary portfolio Synergistic “infectious disease plus” portfolio with 5 approved products Efficient, fully-integrated platform Commercial platform anchored by
Slide 10: IST has a diversified portfolio of high growth hospital and critical care products
Innoviva Specialty Therapeutics Assets IST has a diversified portfolio of high growth hospital and critical care products addressing sizeable markets with significant unmet needs LTM net sales and Product Indication license revenue Selected future growth drivers Vasoconstrictor to increase blood pre
Slide 11: Marketed portfolio has shown consistent quarterly sales growth
Innoviva Specialty Therapeutics Assets Marketed portfolio has shown consistent quarterly sales growth with further support from new product launches Quarterly U.S. net product sales ($M) Giapreza Xerava Xacduro Zevtera Q1 Q2 Q3 Q4 • 10% average quarterly growth since 2023 14.8 17.2 2023 11.4 11.8 •
Slide 12: GIAPREZA: Rapid-acting vasoconstrictor for shock patients
Innoviva Specialty Therapeutics Assets GIAPREZA: Rapid-acting vasoconstrictor for shock patients Indications and usage Key differentiators • GIAPREZA was approved in Dec 2017 to increase blood pressure in adults Unique mechanism of action with septic or other distributive shock, an indication with p
Slide 13: XACDURO: First pathogen-targeted therapy approved for Acinetobacter infections
Innoviva Specialty Therapeutics Assets XACDURO: First pathogen-targeted therapy approved for Best Pharmaceutical Product Nominee 2026 life threatening Acinetobacter infections Indications and usage Key differentiators • XACDURO is the first pathogen-targeted therapy approved for the Only therapy spe
Slide 14: ZEVTERA: First cephalosporin approved for Staph aureus bacteremia
Innoviva Specialty Therapeutics Assets ZEVTERA: First cephalosporin approved for Staph aureus Best Pharmaceutical Product Nominee 2026 bacteremia, including deadly methicillin-resistant strains (MRSA) Indications and usage Key differentiators • ZEVTERA is indicated for treatment of adults with Staph
Slide 15: XERAVA: Broad-spectrum antibiotic for ESBL strains and carbapenem resistance
Innoviva Specialty Therapeutics Assets XERAVA: Broad-spectrum antibiotic with unique strengths to address rising ESBL strains and carbapenem resistance Indications and usage Key differentiators • XERAVA is a tetracycline-class antibiotic approved in August 2018 for the Carbapenem-sparing empiric the
Slide 16: NUZOLVENCE: Single-dose oral antibiotic for gonorrhea in adults
Innoviva Specialty Therapeutics Assets NUZOLVENCE: A first-in-class, single-dose oral antibiotic for Best Pharmaceutical Product Nominee 2026 the treatment of gonorrhea in adults Indications and usage Key differentiators • NUZOLVENCE (zoliflodacin) is a first-in-class, single-dose oral antibiotic ap
Slide 17: Our robust portfolio of strategic healthcare assets in areas of high unmet medical need
Strategic Healthcare Assets Our robust portfolio of strategic healthcare assets in areas of high unmet medical need with significant long-term value creation potential Diversified portfolio consisting of strategic equity, convertible debt investments, and wholly-owned assets in high-potential health
Slide 18: Nortiva Bio has created a disruptive drug delivery system
Nortiva Bio has created a disruptive drug delivery system to enable a new category of long-acting oral medicines A Innovative Founded in MIT's Langer Lab, the LYNX drug delivery platform can TM scientific transform daily oral medicines into once-weekly or once-monthly roots pills • A: The platform u
Slide 19: Armata is an innovator in phage-based anti-infectives
Armata is an innovator in phage-based anti-infectives addressing significant unmet medical need Harnessing significant Leading developer of high-purity, high titer, pathogen-specific phage therapeutics: advantages of phage- • Potential alternative to antibiotics – effective while protecting normal h
Slide 20: We have actively deployed capital to maximize shareholder value
We have actively deployed capital to maximize shareholder value Return of capital to Opportunistic Value-accretive Thoughtful asset Capital structure shareholders asset operating platform acquisitions optimization monetization build out Repurchased GSK’s Monetized Innoviva’s Acquired Entasis and Dep
Slide 21: Innoviva has robust financials with multiple sources of value
Innoviva has robust financials with multiple sources of value $240M $212M LTM Anoro & Breo Royalty LTM Net Product Sales and Revenue License Revenue $681M $670M $261M Equity and Cash and Receivables Convertible Notes Other Investments (as of June 30, 2026) (as of June 30, 2026) (as of June 30, 2026)
Slide 22: Q2 2026 showed ongoing rapid therapeutics growth
Q2 2026 showed ongoing rapid therapeutics growth U.S. net product sales Q2 2025 Q2 2026 YoY growth “Innoviva delivered another strong quarter, supported by durable cash generation from our royalty portfolio and $17.0M $21.0M 24% continued excellent commercial momentum at IST, which achieved 46% year
Slide 23: Innoviva's team has world-class healthcare experience: Management
Innoviva’s team has world-class healthcare experience: Management Key Biopharma, commercial, Superior capabilities and Proven track record of medicine, and capital markets Strong value creation focus attributes network success experience Pavel Raifeld Experienced finance and life sciences operator a
Slide 24: Innoviva's team has world-class healthcare experience: Board of directors
Innoviva’s team has world-class healthcare experience: Board of directors Independent oversight of Experience in healthcare, Innoviva’s capital allocation Key Superior capabilities and investing, capital markets Strong value creation focus strategy and long-term attributes network and governance dev
Slide 25: Thank you
Thank you Investor and media contact: Investors.relations@inva.com
Slide 26: Appendices
Appendices
Slide 27: Key events in the history of Innoviva
Key events in the history of Innoviva Timeline of major Innoviva events First royalty product Third royalty Announced Sale of Trelegy Integration of Announced Zevtera Launch of (Breo) launches in U.S. product (Trelegy) acquisition of Entasis Ellipta Royalty Entasis and La Jolla successful Phase III
Slide 28: Relvar / Breo detail
Royalty assets Relvar / Breo detail: First once-daily inhaled corticosteroid / long-acting beta-agonist for asthma and chronic obstructive pulmonary disease US Ex-US Consensus1 Net global sales ($B) RELVAR® / BREO® 1.8 1.6 • Launched in 2013 as first and only once-daily ICS / LABA in ELLIPTA® 1.6 1.
Slide 29: Anoro detail
Royalty assets Anoro detail: Best-in-class long-acting beta-agonist / long-acting muscarinic antagonist for COPD US Ex-US Consensus1 Net global sales ($B) ANORO® 0.8 0.7 0.7 • Launched in 2014 as first-in- 0.7 class LABA / LAMA single ELLIPTA® 0.7 0.7 0.6 0.7 0.7 0.7 0.7 0.6 0.6 inhaler product in t
Slide 30: XACDURO: Significant ex-U.S. value as many countries have high CRAB prevalence
Innoviva Specialty Therapeutics Assets XACDURO: Significant ex-U.S. value as many countries have high CRAB prevalence Global percentages of carbapenem resistance and incidence of A. baumannii Carbapenem CRAB resistance1,2 incidence3,4,5 United States 45% ~18,400 Latin/South America 86% >80,000 Europ